These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 in the treatment of hematologic malignancies. Fefer A Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S35-6. PubMed ID: 9457391 [No Abstract] [Full Text] [Related]
6. The role of natalizumab in hematopoietic stem cell mobilization. Neumann F; Zohren F; Haas R Expert Opin Biol Ther; 2009 Aug; 9(8):1099-106. PubMed ID: 19566481 [TBL] [Abstract][Full Text] [Related]
8. [The role of interleukin-2--based immunotherapy in hematological malignancies]. Ackerstein A; Toren A; Slavin S; Nagler A Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642 [No Abstract] [Full Text] [Related]
9. Third biannual report of the Cochrane Haematological Malignancies Group. Kober T; Skoetz N; Trelle S; Bohlius J; Engert A; J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014 [No Abstract] [Full Text] [Related]
10. Manipulation of the stem cell as a target for hematologic malignancies. Ballen KK; Becker PS; Stewart FM; Quesenberry PJ Semin Oncol; 2000 Oct; 27(5):512-23. PubMed ID: 11049019 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Nadal E; Fowler A; Kanfer E; Apperley J; Goldman J; Dazzi F Exp Hematol; 2004 Feb; 32(2):218-23. PubMed ID: 15102484 [TBL] [Abstract][Full Text] [Related]
12. Update on non-myeloablative stem cell transplantation for hematologic malignancies. Giralt S Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884 [TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience. Kuthiala SS; Lyman GH; Ballester OF Bone Marrow Transplant; 2006 Jan; 37(2):219-21. PubMed ID: 16299544 [TBL] [Abstract][Full Text] [Related]
14. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Wolff SN Bone Marrow Transplant; 2002 Apr; 29(7):545-52. PubMed ID: 11979301 [TBL] [Abstract][Full Text] [Related]
15. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Niscola P; Romani C; Scaramucci L; Dentamaro T; Cupelli L; Tendas A; Piccioni D; Giovannini M; Tolu B; Cartoni C; Arcuri E; Perrotti A; Palumbo R; de Fabritiis P Bone Marrow Transplant; 2008 May; 41(9):757-64. PubMed ID: 18246112 [TBL] [Abstract][Full Text] [Related]
16. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. Handgretinger R; Kurtzberg J; Egeler RM Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. Margolin K; Forman SJ Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S33-8. PubMed ID: 10685656 [TBL] [Abstract][Full Text] [Related]
18. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Vigorito AC; Marques Júnior JF; Aranha FJ; Oliveira GB; Miranda EC; De Souza CA Haematologica; 2001 Jun; 86(6):665-6. PubMed ID: 11418381 [No Abstract] [Full Text] [Related]
19. [Nonmyeloablative stem cell transplantation as cancer immunotherapy]. Willems E; Baron F; Vanstraelen G; Frère P; Fillet G; Beguin Y Rev Med Suisse; 2005 Aug; 1(30):1973-7. PubMed ID: 16200942 [TBL] [Abstract][Full Text] [Related]